Delhi HC lets Sun Pharma export diabetes drug generic—but not sell in India yet
Sun Pharma just got the green light from the Delhi High Court to make and export a generic version of semaglutide—a popular drug for diabetes and weight loss.
But there's a catch: they can't sell it in India until March 2026, when Novo Nordisk's secondary patent runs out.
The court also wants proof that Sun is following the rules, with an affidavit due in two weeks and a hearing scheduled for February 19, 2026.
Why does this matter?
This move could make semaglutide more affordable in countries where Novo Nordisk doesn't hold patents, opening up access for people who need it.
It's also a big deal for Indian pharma companies—Dr. Reddy's got similar permission—which means more generics might hit global markets while still respecting patent laws at home.
For anyone watching how meds get cheaper (and who gets them), this is one to keep an eye on.